U.S. Markets closed

Cytosorbents Corporation (CTSO)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.350.00 (0.00%)
At close: 4:00PM EDT
People also watch
AEMDELTPADXSONCSTTNP
  • Don't forget to vote your shares before the big meeting. Vote against chanie and the board and let them know what we think of their failure to deliver any positive results and their lying excuses for the failures.
  • Maxim Group set a $10.00 price target on Cytosorbents Corp (NASDAQ:CTSO) in a research note issued to investors on Monday. The brokerage currently has a buy rating on the medical research company’s stock.

    A number of other equities research analysts also recently issued reports on CTSO. B. Riley reaffirmed a buy rating and set a $11.25 price target on shares of Cytosorbents Corp in a research note on Friday, May 5th. HC Wainwright upped their price target on shares of Cytosorbents Corp from $11.50 to $13.00 and gave the company a buy rating in a research note on Monday, March 6th. Finally, Aegis reaffirmed a buy rating and set a $9.00 price target on shares of Cytosorbents Corp in a research note on Tuesday, May 9th. Five equities research analysts have rated the stock with a buy rating, Cytosorbents Corp presently has a consensus rating of Buy and a consensus price target of $13.45.

    Cytosorbents Corp (NASDAQ:CTSO) opened at 4.35 on Monday. The company’s 50 day moving average is $4.61 and its 200 day moving average is $5.24. The company’s market cap is $122.27 million. Cytosorbents Corp has a 12-month low of $3.95 and a 12-month high of $6.90.

    Cytosorbents Corp (NASDAQ:CTSO) last released its earnings results on Monday, May 8th. The medical research company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.06. Cytosorbents Corp had a negative net margin of 120.04% and a negative return on equity of 193.13%. The firm had revenue of $3.11 million for the quarter, compared to the consensus estimate of $2.99 million. Analysts forecast that Cytosorbents Corp will post ($0.28) earnings per share for the current fiscal year.

    Large investors have recently added to or reduced their stakes in the stock. Skylands Capital LLC increased its stake in Cytosorbents Corp by 1,276.5% in the first quarter. Skylands Capital LLC now owns 316,600 shares of the medical research company’s stock worth $1,425,000 after buying an additional 293,600 shares during the last quarter. Segantii Capital Management Ltd increased its stake in Cytosorbents Corp by 563.4% in the first quarter. Segantii Capital Management Ltd now owns 27,200 shares of the medical research company’s stock worth $122,000 after buying an additional 23,100 shares during the last quarter. Cowen Group Inc. acquired a new stake in Cytosorbents Corp during the first quarter worth about $248,000. Vanguard Group Inc. increased its stake in Cytosorbents Corp by 3.9% in the first quarter. Vanguard Group Inc. now owns 567,116 shares of the medical research company’s stock worth $2,552,000 after buying an additional 21,312 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in Cytosorbents Corp by 0.5% in the first quarter. Geode Capital Management LLC now owns 126,883 shares of the medical research company’s stock worth $570,000 after buying an additional 606 shares during the last quarter. 6.07% of the stock is currently owned by institutional investors.
  • Case of the week 20/2017
    Use of CytoSorb in a case of severe septic shock and MOF due to urosepsis

    Heike Keller, Dr. med. M. Schmidt, Dipl.-Med. Dirk Weiland – Werner Forßmann Hospital Eberswalde, Intensive Care Unit of the Department for Anesthesiology and Intensive Care Medicine, Germany
    Summary:

    This case study reports on a 55-year-old severely obese female patient (BMI 50 kg/m2), who presented at the Emergency Center with abdominal symptoms and signs of a generalized infection (tachycardia, hypotonia, tachypnea and hypercapnia).
    Case presentation

    Immediately after admission laboratory diagnostics (blood and urine culture) and CT abdomen were done
    On the basis of proven urinary congestion left, decision taken to implant a bilateral ureteral splint and the patient was operated on after another hour
    In the course of intubation, the patient had to be resuscitated (1 cycle, 1 mg adrenaline)
    After surgery, the patient was transferred to the intensive care unit – intubated, ventilated, hemodynamically unstable and catecholamine-dependent
    Initiation of calculated antibiotic therapy with ciprofloxacin and piperacillin/tazobactam, after the detection of E. coli in the urine culture with de-escalation to piperacillin/tazobactam
    On the 1st postoperative day, development of anuria with a sharp increase in retention parameters (creatinine 554 μmol/l, urea 23.9 mmol/l, GFR 7.2 ml/min) and inflammatory parameters (CRP> 500 mg/l, PCT 350 ng/ml, leukocytes 22.7 GPT/l)
    Progressing hemodynamic instability with increasing doses of norepinephrine (0.3 μg/kg/min) and lactic acidosis (11.8 mmol/l), PICCO: CI 3,73 l/min/m2; EVLWI 12,5ml/m2; ITBVI 1715 ml/m2
    Due to acute renal failure and septic shock with massively increased inflammatory parameters, renal replacement therapy was started in combination with CytoSorb therapy
    Final diagnosis: urosepsis with multiple organ failure (cardiovascular, kidney, lung)
    Treatment

    Four consecutive treatments with CytoSorb for a total treatment time of 96 hours
    CytoSorb was used in conjunction with CRRT (Multifiltrate, Fresenius Medical Care) performed in CVVHD mode
    Blood flow rate: 150 ml/min
    Anticoagulation: initially none, later heparin
    CytoSorb adsorber position: pre-hemofilter
    Measurements

    Advanced hemodynamic monitoring (PiCCO)
    Renal function
    Inflammatory parameters (CRP, PCT, leucocytes)
    Lactate
    Results

    Hemodynamic stabilization with significant reduction in catecholamine dosages – norepinephrine could be reduced from 0.3 μg/kg/min initially to 0.13 μg/kg/min within the first 3 days of treatment
    Significant improvement in renal function
    Within the first 3 days, reduction in leukocytes to 17.2 Gpt/l, CRP to 431 mg l and PCT to 147 ng/ml
    Lactate decreased from 11.8 mmol/l initially to 3.8 mmol/l within the first 3 days of treatment and normalized after 10 days
    Patient Follow-Up

    Tracheotomy on the 8th postoperative day and weaning from mechanical ventilation on the 13th postoperative day
    Termination of renal replacement therapy on the 13th postoperative day, however, further necessity for intermittent dialysis
    In the further course, development of a Critical Illness Myopathy (CIM) and Critical Illness Polyneuropathy (CIP)
    27 days after CytoSorb the patient was discharged straight to rehabilitation
    CONCLUSIONS

    The surgical and intensive care treatment of urosepsis (focus eradication, antibiotic therapy, other sepsis therapies) and the early application of CytoSorb in combination with renal replacement therapy was accompanied by a rapid and significant stabilization of hemodynamics and declining catecholamine dosages as well as a reduction in inflammatory parameters
    According to the medical team, its early use proved to be useful and effective considering the severity of the disease including multi-organ failure
    Safe and easy application of CytoSorb
  • sale is over move on the way $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$ 5.60 by next wed,--bill
  • Good News Today with Aferetica in Italy!
  • The renewed agreement with Aferetica sri, YES, it is good news, but to speculate that $10 mil in units might be sold with Aferetica by 2021 is improper conjecture. Real sales numbers in Italy have been modest at best, and 2) CTSO usage is regularly referenced as a game changer on virtually every serious medical platform... point being where is the real top end in potential sales, why in the world should PR cite a potential $$ figure, reading that sort of babble, is DC committing CEO malpractice while chest pounding at a Milanese conference.
    We NEED TO KNOW is why Q1-17 sales stalled compared to Q4-16.
    Is the Cytosorb salesforce underpaid as DC talks about high product margins ? DC, we continue to lose money , our float has expanded, the leadership appears to be on the stock option gravy train, and we are moving FURTHER AWAY FROM INFLECTION.
  • Sub $4.00! Starting to wonder if we are going to be taken over. Nothing to stop that at these prices. Certainly a big position is being developed.
  • monday is a very big day for investers--bill
  • I wonder if Dr Chan has reached out to the Gates Foundation. They have poured many millions into life saving technologies.
  • Two New Good Cytosorb Publications on PubMed!
  • Profile Now Has 70 Employees.Chan said there would new key hires before the summer.Was 65.
  • Is one of our big problems right now options? Are they keeping the price down til the end of this month? Don't really understand options but just wondering.
  • Hemoadsorption treatment of patients with acute infective endocarditis during surgery with cardiopulmonary bypass - a case series.
    Träger K, et al. Int J Artif Organs. 2017.
    Authors
    Träger K1, Skrabal C2, Fischer G1, Datzmann T1, Schroeder J1, Fritzler D1, Hartmann J1, Liebold A2, Reinelt H1.
    Author information
    1Department of Cardiac Anesthesiology, University Hospital Ulm, Ulm - Germany.
    2Clinic of Cardiothoracic and Vascular Surgery, University Hospital Ulm, Ulm - Germany.
    Citation
    Int J Artif Organs. 2017 May 19:0. doi: 10.5301/ijao.5000583. [Epub ahead of print]
    Abstract
    INTRODUCTION: Infective endocarditis is a serious disease condition. Depending on the causative microorganism and clinical symptoms, cardiac surgery and valve replacement may be needed, posing additional risks to patients who may simultaneously suffer from septic shock. The combination of surgery bacterial spreadout and artificial cardiopulmonary bypass (CPB) surfaces results in a release of key inflammatory mediators leading to an overshooting systemic hyperinflammatory state frequently associated with compromised hemodynamic and organ function. Hemoadsorption might represent a potential approach to control the hyperinflammatory systemic reaction associated with the procedure itself and subsequent clinical conditions by reducing a broad range of immuno-regulatory mediators.

    METHODS: We describe 39 cardiac surgery patients with proven acute infective endocarditis obtaining valve replacement during CPB surgery in combination with intraoperative CytoSorb hemoadsorption. In comparison, we evaluated a historical group of 28 patients with infective endocarditis undergoing CPB surgery without intraoperative hemoadsorption.

    RESULTS: CytoSorb treatment was associated with a mitigated postoperative response of key cytokines and clinical metabolic parameters. Moreover, patients showed hemodynamic stability during and after the operation while the need for vasopressors was less pronounced within hours after completion of the procedure, which possibly could be attributed to the additional CytoSorb treatment. Intraoperative hemoperfusion treatment was well tolerated and safe without the occurrence of any CytoSorb device-related adverse event.

    CONCLUSIONS: Thus, this interventional approach may open up potentially promising therapeutic options for critically-ill patients with acute infective endocarditis during and after cardiac surgery, with cytokine reduction, improved hemodynamic stability and organ function as seen in our patients.

    PMID 28525670 [PubMed - as supplied by publisher]
  • Case of the week 19/2017

    Use of CytoSorb in Streptococcus pneumoniae Sepsis
    Dr. med. Marcel Frimmel1, Christine Nauk2, PD Dr. med Friedhelm Sayk1 Sana Clinics Lübeck GmbH 1 Interdisciplinary Intensive Care Medicine 2 Medical Clinic I – Gastroenterology, Pneumology, Diabetes and Internal Medicine, Pneumology Section

    Summary:
    This case study reports on a 69-year-old patient (pre-existing medical history: lung carcinoma with upper and lower right lobe resection one year before), admitted to hospital via emergency transport with fever, respiratory insufficiency, hemodynamic instability as well as signs of sepsis.

    Case presentation
    Direct transfer to intensive care unit with non-invasive ventilation
    Intubated and ventilated due to respiratory exhaustion (PaO2/FiO2 ratio of 150)
    High-dose antibiotic therapy with piperacillin/tazobactam and clarithromycin
    The CT showed infiltrates in the right upper lobe and the diagnosis of pneumonia was made
    Subsequently multiple bronchoscopies with detection of Streptococcus pneumioniae (mucoid form)
    Development of severe hemodynamic instability with the need for very high doses of catecholamines (norepinephrine 9.6 mg/h, terlipressin 0.16 mg/h) and maximum volume therapy 1 l/h (15 liters/20 hours)
    The patient had to be resuscitated (1 reanimation cycle) as a result of slight repositioning maneuvers, his circulation could be restored with an infusion of adrenaline however he remained hemodynamically unstable
    Highly elevated inflammatory parameters (CRP 406 mg/l, leukocytes 18 E9/l, PCT 160 ng/ml) as well as severe impairment in renal function (creatinine 4.3 mg/dl, GFR 14 ml/min/m2)
    Due to renal failure, metabolic acidosis (pH 7.07, lactate 8 mmol/l) and hemodynamic instability with further increasing norepinephrine doses the decision was made to start renal replacement therapy together with CytoSorb

    Treatment
    Three treatments with CytoSorb for a total treatment period of 50 hours (6 hours, 20 hours, 24 hours)
    CytoSorb was used in conjunction with CRRT (Multifiltrate, Fresenius Medical Care) performed in CVVHD mode
    Blood flow rate: 100-150 ml/min
    Anticoagulation: heparin
    CytoSorb adsorber position: pre-hemofilter

    Measurements
    Demand for catecholamines
    Inflammatory parameters (CRP, PCT, leukocytes)
    Metabolic variables (lactate, pH)
    Renal function

    Results
    Hemodynamic stabilization with a significant reduction in catecholamine doses –  norepinephrine halved within the first 24 hours and could be consistently reduced in the further course
    Clear reduction in inflammatory parameters (PCT halved from day to day, with 78 ng/ml already after the first 24 hours, CRP from 400 mg/l to 275 mg/l, leukocytes from 18 E9/l to 13 E9/l and later to 10 E9/l)
    Lactate (from 5 to 2 mmol/l) and  pH (from 7.0 to 7.3) improved significantly throughout the course of the treatments and normalized
    Improvement in renal function
    Clear improvement in oxygenation index to over 200

    Patient Follow-Up
    In the further course the patient had to be  tracheotomized, however he was awake, oriented and able to mobilize
    Patient is still planned for right lobectomy due to suspicion of a persisting infective focus

    CONCLUSIONS
    Rapid hemodynamic stabilization resulting in a reversal of the shock state with otherwise exhausted therapy
    The rapid initiation of treatment in ICU with the combination of appropriate antibiotics, CytoSorb and CVVHD enabled an effective stabilization of the patient´s clinical situation
    The installation of the CytoSorb absorber into the CVVHD circuit was simple and safe
  • When will everyone "WAKE UP" and realize "DR CHAN" IS THE PROBLEM..We have the greatest product out there, and yet we are CONSTANTLY IN THE RED... Our stock price is "LOWER THAN IT WAS EIGHT YEARS AGO WHEN DR CHAN JOINED ON" . And this is "AFTER" A "REVERSE SPLIT"..I really didn't think about this until I read it on a post on Ihub..This man needs to be "Demoted"..Any real CEO would have HIRED A PROFESSIONAL PR FIRM TO GET THE WORD OUT TO "BIG INVESTORS". I have had enough of this man and our many excuses for him. His "STUMBLING SPEECHES" at the Q reports are also hurting us. "Let someone else who has taken a professional speech class talk. They will make the exciting news "SOUND EXCITING". His fumbling, boring monotone speak is killing any excitement that should come from the news. The Board of Directors must be full of his relatives because "ANY REAL BOARD OF DIRECTORS WOULD HAVE DEMOTED THIS MAN BY NOW"..Days and weeks when the stock market is "BREAKING RECORDS", we are in the red. NO MORE EXCUSES, THIS MAN NEEDS TO GO
  • Wow! $4.10 close. Would be tempted to place a $3.95 bid for tomorrow if we didn't have to wait until November to see if sales in Germany increase as predicted. Could go lower, so I wait on the sidelines (to add as a long term bagholder).
  • Thank god we are up .03 today now I can get some sleep. Hope I didn't jinx us.
  • I would speculate that the lack of large scale clinical studies still present a challenge to the sale force. I suspect that most hospitals end up dipping their toes in the water with Cytosorb slowly, with their own evaluation of the product. It is encouraging that a hospital has hit the 1 million mark, as it tells us that the early adopters are liking the results they are seeing.
  • Maybe Chan has something up his sleeve to break the downturn.

    Feeling pathetically hopeful
  • How so we go about finding out what is going on with Biocon efforts? Also same question about the Middle East distributor. There has been no mention of them for over a year and they have been distributors for over two years. Actually Biocon is more like 3 years. There was so much hype but seems no sales. Why isn't management updating us?